The World in a Grain of Sand: Amylyx Pharmaceuticals

The World In A Grain Of Sand

Contenu fourni par KdT Ventures. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par KdT Ventures ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.

1+ y ago 34:33

M4A•Maison d'episode

KdT Ventures Partners, Mack Healy & Rima Chakrabarti take a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This episode, Amylyx Pharmaceuticals, a neuro biotech founded in a dorm room by two scrappy Brown undergrads. We discuss:

the mechanism of action of Amylyx’s lead disease-modifying asset, and competitive positioning relative to other treatments for neurodegeneration such as aducanumab
Amylyx’s capital efficiency, and reaching PhII trials without a single institutional investor
Amylyx’s unique engagement of ALS patients from the earliest days of the company, helping ensure a strong commercial launch of their ALS therapy
and more

For updates from KdT, please subscribe to our Substack.

13 episodes

#Trading #Business #KdT Ventures